Abstract:
Objective: A simple, sensitive, and accurate in-vitro dissolution method has been developed for Olmesartan Medoxomil (OLM), Chlorthalidone (CHLR) & Cilnidipine (CIL) drug combination according to USP dissolution testing methodologies with different discriminating mediums and validated as per ICH guidelines.
Methods: The in-vitro dissolution prole was obtained using 900 ml of phosphate buffer pH 6.8 with 1.0% SLS at 37 °C ± 0.5 °C as dissolution medium and USP II (paddle) at 75 rpm. The average % in-vitro drug release was above 80% within 45 minutes for the above drug
combination. The drug release prole was evaluated by RP-HPLC method. Chromatographic
separation was done on Hypersil-BDS C-18 (12.5cm x 4.6mm x 5μm) column using gradient
program with initial mobile phase ratio of 55:45 (v/v) mixture of ammonium acetate buffer (pH 5.0) and acetonitrile at a ow rate of 1.0 ml/min with detection wavelength 260 nm.
Results: The method was validated with respect to specicity, linearity, precision, accuracy, and robustness. The method was found to be linear in the range of 7.0-21.0 μg/ml for CHLR (R =.9982), 22.5-67.5 μg/ml for OLM (R = 0.9999) and 5.5 -16.5 μg/ml for CIL (R = 0.9995)
respectively. The % recovery data were found between 98.3 % to 104.1%. The % RSD for
method and intermediate precision of method did not exceed more than 2%.
Conclusion: The proposed in-vitro method can be applied successfully for routine quality
control analysis to check the quality of above drug combination.
